Submit a Letter to the Editor for:
Christopher Kornfeld, Mickaël J.-Y. Ploquin, Ivona Pandrea, Abdourahmane Faye, Richard Onanga, Cristian Apetrei, Virginie Poaty-Mavoungou, Pierre Rouquet, Jérôme Estaquier, Lorenzo Mortara, Jean-François Desoutter, Cécile Butor, Roger Le Grand, Pierre Roques, François Simon, Françoise Barré-Sinoussi, Ousmane M. Diop, Michaela C. Müller-Trutwin
J Clin Invest. 2005;
115(4):1082
doi:10.1172/JCI23006
Abstract |
Full text
|
PDF
T
cell activation levels in HIV infection are predictive of AIDS progression. We searched for the immunological correlates of protection against disease progression by studying the early stages of nonpathogenic SIV infection in African green monkeys (SIVagm). The African green monkeys (AGMs) displayed high peak viremias and a transient decline in levels of blood CD4+ and CD8+ T cells between days 5 and 17 after infection. A concomitant increase in levels of CD4+DR+, CD8+DR+, and CD8+CD28– cells was detected. After the third week, T cell activation returned to baseline levels, which suggested a protective downregulation of T cell activation. A very early (24 hours after infection) and strong induction of TGF-β1 and FoxP3 expression was detected and correlated with increases in levels of CD4+CD25+ and CD8+CD25+ T cells. This was followed by a significant increase in levels of IL-10, whereas IFN-γ gene upregulation was more transient, and levels of TNF-α and MIP-1α/β transcripts did not increase in either blood or tissues. The profiles were significantly different during primary SIV infection in macaques (SIVmac); that is, there was a delayed increase in IL-10 levels accompanied by moderate and persistent increases in TGF-β levels. Together, our data show that SIVagm infection is associated with an immediate antiinflammatory environment and suggest that TGF-β may participate in the generation of Tregs, which may prevent an aberrant chronic T cell hyperactivation.
Guidelines:
The Editorial Board will only consider letters that we deem relevant and of interest to our readers. We will not post data that have not been subjected to peer review, nor will we post letters that are essentially a reiteration of another letter. All accepted letters will be posted on our website within one week of acceptance. The Editors reserve the right to edit any letter for length, content, and clarity. Authors of all accepted letters will be asked to preview any changes. Authors will be notified by e-mail if their letters were not accepted. As this is a final decision, no appeals will be considered.
Specific requirements: All letters must be 400 words or fewer. You may enter the letter as plain text or HTML, if you wish. The author's name and e-mail address are required, and will be posted with the letter. All possible conflicts of interest must be noted, even if they are not posted. If you wish to include a figure (keep in mind that non-peer-reviewed data will not be posted), please contact the editor directly at editors@the-jci.org.
